Anson Funds Management LP Takes $297,000 Position in Tenax Therapeutics Inc (TENX)

Anson Funds Management LP bought a new stake in shares of Tenax Therapeutics Inc (NASDAQ:TENX) in the 4th quarter, Holdings Channel reports. The fund bought 607,097 shares of the specialty pharmaceutical company’s stock, valued at approximately $297,000.

Tenax Therapeutics Inc (NASDAQ TENX) opened at $8.19 on Wednesday. The firm has a market cap of $11.56, a P/E ratio of -0.31 and a beta of 1.69. Tenax Therapeutics Inc has a 1-year low of $4.40 and a 1-year high of $15.80.

Separately, ValuEngine raised shares of Tenax Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

TRADEMARK VIOLATION WARNING: “Anson Funds Management LP Takes $297,000 Position in Tenax Therapeutics Inc (TENX)” was originally posted by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company’s main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure.

Want to see what other hedge funds are holding TENX? Visit to get the latest 13F filings and insider trades for Tenax Therapeutics Inc (NASDAQ:TENX).

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply